All Events

Filter by

Event Date

Filter by Event Date

Done
NIH
Bethesda, MD
In September 2014, a working group heard presentations on scientific evidence that sex is a major determinant for the development and progression of cardiovascular disease. Afterward, the group recommended actions that can be taken to promote more research into the impact of sex on cardiovascular health.
September 24 - 25, 2014
NIH
Bethesda, MD
The Division of Lung Diseases of the NHLBI convened a workshop on September 25-26, 2014, to identify needed research to advance the targeted delivery of drugs and imaging probes for preventing and treating lung diseases.
NC Biotech Center
Research Triangle Park, NC
The 2014 Regional Innovation Conference-Southeast was held on Monday, September 22, 2014 at the NC Biotech Center in Research Triangle Park. There were approximately 150 attendees including NHLBI Small Business Awardees and investors from leading companies in the southeast United States.
NIH
Bethesda, MD
Asthma is a common chronic disease without cure. To address this important clinical condition, The NHLBI convened a group of extramural investigators on September 18–19, 2014, to accelerate discoveries and their translation to patients.
NIH
Bethesda, MD
The NHLBI convened this November 2014 workshop to discuss the results of recent research on the effects of inorganic nitrate and nitrite on the cardiovascular system.
NIH
Bethesda, MD
During this November 2014 teleconference, federal agencies provided updates on their efforts to improve understanding, treatment, and awareness of COPD.
September 9 - 10, 2014
NIH
Bethesda, MD
The 259th meeting of the National Heart, Lung, and Blood Advisory Council (NHLBAC) was convened on Tuesday, September 9, and Wednesday, September 10, 2014, in Building 35A, Conference Rooms 610/620-630/640, National Institutes of Health (NIH), Bethesda, Maryland.
September 7 - 8, 2014
NIH
Bethesda, MD
In September 2014, the NHLBI convened a group of experts in the areas of cardiovascular risk assessment, treatment of blood cholesterol to reduce cardiovascular risk, and implementation and dissemination to identify gaps in current lipid and cardiovascular disease risk assessment guidelines.